Table 1 Associations between SATB1 expression, clinicopathological and molecular parameters in all patients, and patients with colon and rectal cancer
From: Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer
SATB1 Expression | Negative | Intermediate | High | |
|---|---|---|---|---|
n(%) | 307(58.0) | 126(23.8) | 96(18.1) | p-value§ |
(R) | ||||
Age | ||||
<=75 | 208(67.8) | 86(68.3) | 67(69.8) | 0.736 |
>75 | 99(32.2) | 40(31.7) | 29(30.2) | (−0.011) |
Gender | ||||
Female | 152(49.5) | 71(56.3) | 60(62.5) | 0.020* |
Male | 155(50.5) | 55(43.7) | 36(37.5) | (−0.097) |
T-stage | ||||
1-2 | 54(18.2) | 30(26.1) | 24(25.8) | 0.350 |
3 | 200(67.3) | 67(58.3) | 52(55.9) | (−0.042) |
4 | 43(14.5) | 18(15.7) | 17(18.3) | |
missing | 10 | 11 | 3 | |
N-Stage | ||||
0 | 165(58.1 | 64(59.8) | 55(61.8) | 0.719 |
1 | 74(26.1) | 19(17.8) | 21(23.6) | (−0.007) |
2 | 45(15.8) | 24(22.4) | 13(14.6) | |
missing | 23 | 19 | 7 | |
M-stage | ||||
0 | 252(83.4) | 92(74.2) | 85(89.5) | 0.977 |
1 | 50(16.6) | 32(25.8) | 10(10.5) | (0.036) |
missing | 5 | 2 | 1 | |
Differentiation grade | ||||
Intermediate-High | 233(77.2) | 99(80.5) | 70(75.3) | 0.964 |
Low | 69(22.8) | 24(19.5) | 23(24.7) | (−0.009) |
missing | 5 | 3 | 3 | |
Vascular invasion | ||||
No | 89(47.8) | 30(46.2) | 29(52.7) | 0.696 |
Yes | 97(52.2) | 35(53.8) | 26(47.3) | (−0.013) |
missing | 121 | 61 | 41 | |
MSI screening status | ||||
MSS | 227(78.3) | 111(94.9) | 87(92.6) | <0.001** |
MSI | 63(21.7) | 6(5.1) | 7(7.4) | (−0.212) |
missing | 17 | 11 | 2 | |
Betacatenin grade | ||||
0 | 99(33.2 | 37(30.8) | 16(16.8) | <0.001** |
1 | 105(35.2) | 35(29.2) | 26(27.4) | (0.154) |
2 | 94(31.5) | 48(40.0) | 53(55.8) | |
missing | 9 | 6 | 1 | |
SATB2 expression | ||||
negative | 125(42.2) | 22(11.2) | 0(0.0) | <0.001** |
intermediate | 133(44.9) | 76(63.9) | 41(43.2) | (0.392) |
high | 38(12.8) | 21(17.6) | 54(56.8) | |
missing | 11 | 7 | 1 |